Key result
Higher fasting serum ANGPTL3 levels were independently associated with an increased risk of metabolic syndrome in patients with coronary artery disease.
Why the study?
ANGPTL3 regulates triglyceride metabolism, and MetS is an independent cardiovascular risk factor, but the relationship between fasting serum ANGPTL3 levels and MetS in CAD patients required evaluation.
Does fasting serum ANGPTL3 level correlate with metabolic syndrome in patients with coronary artery disease?
Cross-Sectional (n=90)
No
Does fasting serum ANGPTL3 level correlate with metabolic syndrome in patients with coronary artery disease?
Answers are grounded in this paper and cite their sources.
Fasting serum ANGPTL3 levels are positively associated with and independently predict the presence of metabolic syndrome in patients with coronary artery disease.
Objectives: Angiopoietin-like protein 3 (ANGPTL3) regulates triglyceride metabolism by reversibly inhibiting the lipoprotein lipase activity. Metabolic syndrome (MetS) is an independent risk factor for further cardiovascular disease. This study evaluated the relationship between the fasting serum ANGPTL3 levels and MetS in patients with coronary artery disease (CAD). Materials and Methods: Fasting blood samples were obtained from 90 patients with CAD. Serum ANGPTL3 levels were measured using a commercial enzyme-linked immunosorbent assay kit. MetS and its components were defined using the diagnostic criteria of the International Diabetes Federation. Results: Fifty-three patients (58.9%) had MetS. The hypertension ( P = 0.001), diabetes ( P < 0.001), body weight ( P = 0.027), body mass index ( P = 0.001), waist circumference ( P < 0.001), systolic blood pressure ( P = 0.001), fasting glucose ( P < 0.001), triglycerides ( P < 0.001), blood urea nitrogen ( P = 0.044), C-reactive protein ( P = 0.010), insulin ( P = 0.040), homeostasis model assessment of insulin resistance ( P = 0.002), and ANGPTL3 level ( P = 0.001) of CAD patients who had MetS were higher, and the high-density lipoprotein cholesterol ( P = 0.001) and estimated glomerular filtration rate ( P = 0.016) were lower. A binary logistic regression analysis of the significant variables also revealed that the ANGPTL3 level (odds ratio: 1.023, 95% confidence interval: 1.008–1.038, P = 0.002) was an independent predictor of MetS in patients with CAD. Conclusion: The results of our study indicated that the fasting ANGPTL3 level was positively associated with MetS among patients with CAD.
No takes yet. Share an insight, caveat, or question.
Lian et al. (2021) conducted a cross-sectional in Coronary artery disease and metabolic syndrome (n=90). Fasting serum ANGPTL3 level vs. Lower ANGPTL3 levels was evaluated on Presence of metabolic syndrome (OR 1.023, 95% CI 1.008-1.038, p=0.002). Higher fasting serum ANGPTL3 levels were independently associated with an increased risk of metabolic syndrome in patients with coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: